Understanding Sex Chromosome Loss in Stem Cell Transplants
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains a primary curative therapy for various hematologic malignancies, including leukemias and lymphomas. In many clinical scenarios, patients receive grafts from donors of the opposite sex, known as sex-mismatched transplants. One curious phenomenon observed during post-transplant monitoring is sex chromosome loss (SCL). SCL refers to the disappearance of the Y chromosome in male cells or an X chromosome in female cells. While SCL is known to occur naturally as part of the aging process in healthy individuals, its appearance after a high-stakes procedure like a stem cell transplant has long puzzled clinicians. Does it represent a benign physiological change, or is it a harbinger of disease recurrence? A recent retrospective study published in Bone Marrow Transplantation aims to clarify the clinical significance of SCL and provides a potential threshold for identifying patients at high risk for treatment failure.
